Status:
RECRUITING
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
Lead Sponsor:
Assiut University
Conditions:
HCC
Hepatocellular Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.
Eligibility Criteria
Inclusion
- Age of all studied subjects ≥ 18 years old
- All patients with hepatocellular carcinoma will be included in group I.
- Patients not treated with systemic TKIs
Exclusion
- Patients presented with liver tumors other than HCC.
- Patients with Child-Pugh grade C for liver function.
- Patients with other malignancies.
- Patients with chronic inflammatory disorders.
- Patients with severe organ dysfunction such as heart, lung, and kidney.
- Patients who cannot tolerate or are allergic to sorafenib.
- Patients with severe coagulation dysfunction were uncorrectable.
- Age less than 18 years old.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06527495
Start Date
January 1 2023
End Date
December 1 2024
Last Update
July 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NLI
Shibīn al Kawm, Menoufia, Egypt, 32511